Tiopronin

Tiopronin
Skeletal formula of tiopronin
Names
IUPAC name
N-(2-Sulfanylpropanoyl)glycine
Systematic IUPAC name
(2-Sulfanylpropanamido)acetic acid
Other names
2-mercaptopropionylglycine
Acadione
Identifiers
3D model (JSmol)
1859822
ChEMBL
ChemSpider
ECHA InfoCard 100.016.163 Edit this at Wikidata
EC Number
  • 217-778-4
KEGG
MeSH Tiopronin
RTECS number
  • MC0596500
UNII
  • InChI=1S/C5H9NO3S/c1-3(10)5(9)6-2-4(7)8/h3,10H,2H2,1H3,(H,6,9)(H,7,8) checkY
    Key: YTGJWQPHMWSCST-UHFFFAOYSA-N checkY
  • CC(S)C(=O)NCC(O)=O
Properties
C5H9NO3S
Molar mass 163.19 g·mol−1
Appearance White, opaque crystals
Melting point 93 to 98 °C (199 to 208 °F; 366 to 371 K)
log P −0.674
Acidity (pKa) 3.356
Basicity (pKb) 10.641
Pharmacology
G04BX16 (WHO) QG04BX16 (WHO)
By mouth
Legal status
Hazards
GHS labelling:
GHS07: Exclamation mark
Warning
H302
Lethal dose or concentration (LD, LC):
1,300 mg kg−1 (oral, rat)
Related compounds
Related alkanoic acids
Related compounds
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
checkY verify (what is checkY☒N ?)
Tiopronin
Clinical data
Trade namesThiola
License data
Identifiers
DrugBank
ChEBI
CompTox Dashboard (EPA)
ECHA InfoCard100.016.163 Edit this at Wikidata

Tiopronin, sold under the brand name Thiola, is a medication used to control the rate of cystine precipitation and excretion in the disease cystinuria.[3][4]

It is available as a generic medication.[5][6]

  1. ^ "Thiola- tiopronin tablet, sugar coated". DailyMed. Retrieved 18 June 2021.
  2. ^ "Thiola EC- tiopronin tablet, delayed release". DailyMed. 15 March 2021. Retrieved 6 March 2023.
  3. ^ Lindell A, Denneberg T, Hellgren E, Jeppsson JO, Tiselius HG (1995). "Clinical course and cystine stone formation during tiopronin treatment". Urological Research. 23 (2): 111–7. doi:10.1007/BF00307941. PMID 7676533. S2CID 34308815.
  4. ^ Coe FL, Parks JH, Asplin JR (October 1992). "The pathogenesis and treatment of kidney stones". The New England Journal of Medicine. 327 (16): 1141–52. doi:10.1056/NEJM199210153271607. PMID 1528210.
  5. ^ "Competitive Generic Therapy Approvals". U.S. Food and Drug Administration (FDA). 29 June 2023. Archived from the original on 29 June 2023. Retrieved 29 June 2023.
  6. ^ "First Generic Drug Approvals 2023". U.S. Food and Drug Administration (FDA). 30 May 2023. Archived from the original on 30 June 2023. Retrieved 30 June 2023.

From Wikipedia, the free encyclopedia · View on Wikipedia

Developed by Tubidy